Figure 7. Inhibition of HDAC6 decreases metastasis in the xenograft models of BCa.

A. Representative images of bioluminescence (BLI) of mice orthotopically injected with MDA-MB-231LN cells; first day of treatment (week 0 of treatment (top), week 1 post injection) and after 2 weeks of treatment (bottom) with the vehicle, MLN8237, Tubastatin A and a combination. B. Quantification of the primary tumor growth based on BLI, n=6/group, mean total photon flux +/−S.E.M, two-way ANOVA, p values are non-significant (ns) p=0.6513 for week 2 in all treatment groups. C. Representative images of H&E staining used for quantification of metastatic foci in sections of the lungs from animals as in (A, bottom) (Vehicle, Tubastatin A). The scale bar is 100μm. D. Quantification of the number of metastases in the lungs of orthotopically injected animals at 2 weeks post treatment by a pathologist using serial sections of the lungs and H&E staining. Results are a mean number of metastases per mm² +/−S.E.M, n=6 per treatment group, two-way ANOVA *p=0.0001 for Vehicle/MLN, **p=0.0094 Vehicle/TubA, ***p=0.0012 for Vehicle/MLN+TubA, ns for TubA/MLN+TubA. E. Representative images of BLI; mice intravenously injected with the MDA-MB-231LN cells; Top: Vehicle, ACY1215 or Tubastatin A (week 0, no treatment; 24h post injection). Bottom: 2weeks post treatment, end point. F. Representative images of H&E staining used for quantification of metastatic foci in sections of the lungs from animals as in (E) 2 weeks post treatment (Vehicle, Tubastatin A). The scale bar is 100μm. G. Quantification of the number of metastases in the lungs of intravenously injected animals at 2 weeks post treatment. Results are the mean number of metastases per mm² +/−S.E.M, n=6 per treatment group, one-way ANOVA with pairwise comparison *p=0.0358 for Vehicle/ACY, **p=0.0318 Vehicle/TubA, ns for ACY/ TubA.